#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Evaluation of a nanophosphor lateral-flow assay for self-testing for herpes simplex virus type 2 seropositivity


Autoři: Heather J. Goux aff001;  Balakrishnan Raja aff002;  Katerina Kourentzi aff003;  João R. C. Trabuco aff003;  Binh V. Vu aff003;  Andrew S. Paterson aff002;  Alexander Kirkpatrick aff002;  Blane Townsend aff002;  Miles Lee aff002;  Van Thi Thanh Truong aff004;  Claudia Pedroza aff004;  Richard C. Willson aff001
Působiště autorů: Department of Biology and Biochemistry, University of Houston, Houston, Texas, United States of America aff001;  Luminostics, Inc., San Jose, California, United States of America aff002;  Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, United States of America aff003;  Medical School Center for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0225365

Souhrn

Herpes Simplex Virus Type 2 (HSV-2) is a common human pathogen that causes life-long illness. The US prevalence of HSV-2 infection is 11.9% for individuals between 15 and 49 years of age. Individuals with HSV-2 infection are more likely to contract and spread other sexually-transmitted infections. Eighty percent of individuals with HSV-2 are unaware of their infection, in part because of the social stigma associated with in-clinic testing for sexually-transmitted infections. We conducted an initial evaluation of a prototype smartphone-based serological lateral-flow immunoassay (LFA) for HSV-2 infection that uses strontium aluminate persistent luminescent nanoparticles (nanophosphors) as reporters. When applied to a test panel of 21 human plasma/serum samples varying in anti-HSV titer, the nanophosphor HSV-2 LFA had 96.7% sensitivity and 100% specificity for detection of HSV-2 infection. The sensitivity of the nanophosphor HSV-2 LFA was higher than that of commercially-available rapid HSV-2 assays tested with the same panel. Analysis of the iPhone nanophosphor HSV-2 LFA strip images with our custom smartphone app gave greater reproducibility compared to ImageJ analysis of strip images. The smartphone-based nanophosphor LFA technology shows promise for private self-testing for sexually-transmitted infections (STI).

Klíčová slova:

Apps – Cell phones – Enzyme-linked immunoassays – Herpes simplex virus-2 – Image analysis – Nanoparticles – Strontium – Cross reactivity


Zdroje

1. McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016. NCHS Data Brief. 2018; 1–8.

2. Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis. 1994;21: S38–44. 8042114

3. Sudenga SL, Kempf M-C, McGwin G Jr, Wilson CM, Hook EW 3rd, Shrestha S. Incidence, prevalence, and epidemiology of herpes simplex virus-2 in HIV-1-positive and HIV-1-negative adolescents. Sex Transm Dis. 2012;39 : 300–305. doi: 10.1097/OLQ.0b013e318244a90f 22421698

4. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75 : 3–17. doi: 10.1136/sti.75.1.3 10448335

5. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. journals.lww.com; 2006;20 : 73–83.

6. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res. 2012;10 : 228–237. doi: 10.2174/157016212800618156 22384842

7. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35 : 435–445. doi: 10.1097/00126334-200404150-00001 15021308

8. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116 : 197–202. doi: 10.7326/0003-4819-116-3-197 1309413

9. Johnston C, Corey L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev. 2016;29 : 149–161. doi: 10.1128/CMR.00043-15 26561565

10. Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang M-L, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011;203 : 180–187. doi: 10.1093/infdis/jiq035 21288817

11. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342 : 844–850. doi: 10.1056/NEJM200003233421203 10727588

12. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350 : 11–20. doi: 10.1056/NEJMoa035144 14702423

13. Corey L, Ashley R, Valaciclovir HSV Transmission Study Group. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes. 2004;11 Suppl 3 : 170A–174A.

14. Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169 : 1233–1240. doi: 10.1001/archinternmed.2009.177 19597073

15. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001;285 : 3100–3106. doi: 10.1001/jama.285.24.3100 11427138

16. Gottlieb SL, Douglas JM Jr, Foster M, Schmid DS, Newman DR, Baron AE, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190 : 1059–1067. doi: 10.1086/423323 15319854

17. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35: S173–82. doi: 10.1086/342104 12353203

18. Guerry SL, Bauer HM, Klausner JD, Branagan B, Kerndt PR, Allen BG, et al. Recommendations for the selective use of herpes simplex virus type 2 serological tests. Clin Infect Dis. 2005;40 : 38–45. doi: 10.1086/426438 15614690

19. Feltner C, Grodensky C, Ebel C, Middleton JC, Harris RP, Ashok M, et al. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316 : 2531–2543. doi: 10.1001/jama.2016.17138 27997660

20. LeGoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11 : 83. doi: 10.1186/1743-422X-11-83 24885431

21. Giljohann DA, Mirkin CA. Drivers of biodiagnostic development. Nature. nature.com; 2009;462 : 461–464.

22. Chun P. Colloidal Gold and Other Labels for Lateral Flow Immunoassays. In: Wong R, Tse H, editors. Lateral Flow Immunoassay. Totowa, NJ: Humana Press; 2009. pp. 1–19.

23. Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem. 2009;393 : 569–582. doi: 10.1007/s00216-008-2287-2 18696055

24. Laderman EI, Whitworth E, Dumaual E, Jones M, Hudak A, Hogrefe W, et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol. 2008;15 : 159–163. doi: 10.1128/CVI.00218-07 18003814

25. O’Farrell B. Evolution in Lateral Flow–Based Immunoassay Systems. In: Wong R, Tse H, editors. Lateral Flow Immunoassay. Totowa, NJ: Humana Press; 2009. pp. 1–33.

26. Paterson AS, Raja B, Garvey G, Kolhatkar A, Hagström AEV, Kourentzi K, et al. Persistent luminescence strontium aluminate nanoparticles as reporters in lateral flow assays. Anal Chem. 2014;86 : 9481–9488. doi: 10.1021/ac5012624 25247754

27. Finley E, Cobb A, Duke A, Paterson A, Brgoch J. Optimizing Blue Persistent Luminescence in (Sr1-δBaδ)2MgSi2O7:Eu2+,Dy3+ via Solid Solution for Use in Point-of-Care Diagnostics. ACS Appl Mater Interfaces. 2016;8 : 26956–26963. doi: 10.1021/acsami.6b10303 27635436

28. Paterson AS, Raja B, Mandadi V, Townsend B, Lee M, Buell A, et al. A low-cost smartphone-based platform for highly sensitive point-of-care testing with persistent luminescent phosphors. Lab Chip. 2017;17 : 1051–1059. doi: 10.1039/c6lc01167e 28154873

29. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9 : 671–675. doi: 10.1038/nmeth.2089 22930834

30. Herpes—Q & A—2015 STD Treatment Guidelines [Internet]. [cited 5 Mar 2018]. https://www.cdc.gov/std/tg2015/qa/herpes-qa.htm

31. Schmid DS, Brown DR, Nisenbaum R, Burke RL, Alexander D, Ashley R, et al. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J Clin Microbiol. 1999;37 : 376–379. 9889222

32. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes. 2002;9 : 38–45. 12106510

33. New CDC Treatment Guidelines Promote Use of HerpeSelect(R) Type -⁠ Specific Serology Tests to Help Diagnose Genital Herpes [Internet]. PR Newswire; New York. New York, United States, New York: PR Newswire Association LLC; 2002. pp. 1–1. http://search.proquest.com/docview/449052089

34. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15 : 155–163. doi: 10.1016/j.jcm.2016.02.012 27330520

35. Jun W, Hu R, Hyland L, Crandall D, Ramachandran P, Pangarkar C, et al. Expression and characterization of the soluble form of recombinant mature HSV-2 glycoprotein G for use in anti-HSV-2 IgG serodiagnostic immunoassay. J Virol Methods. 2018;252 : 65–69. doi: 10.1016/j.jviromet.2017.10.021 29104048

36. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014;209 : 325–333. doi: 10.1093/infdis/jit458 24136792

37. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl. 1996;100 : 27–32. 9163020


Článek vyšel v časopise

PLOS One


2019 Číslo 12
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

BONE ACADEMY 2025
nový kurz
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#